PAVmed (NASDAQ:PAVM) Inc (NASDAQ: PAVM) is a diversified industrial innovation company focused on developing and commercializing novel medical technologies across multiple therapeutic platforms. The company’s mission is to address critical unmet needs in patient care by designing and delivering device-based therapies that improve clinical outcomes, reduce procedural complexity, and lower overall healthcare costs. PAVmed’s research and development efforts span endoscopic interventions, interventional oncology, surgical tools, and pain management solutions.
Within its endoscopy platform, PAVmed is advancing a suite of devices designed for tissue capture, resection, and preservation. Key candidates include an endoscopic submucosal dissection kit engineered to simplify mucosal resection procedures and a proprietary rectal preservation system that uses controlled suction to stabilize tissue during transanal surgery. In its interventional oncology pipeline, the company is developing targeted drug-delivery technologies aimed at delivering chemotherapeutic agents directly to tumor sites. Additional programs focus on minimally invasive surgical retractors and neuromodulation devices intended to treat chronic pain without the need for implantable hardware.
Headquartered in New York, PAVmed conducts clinical studies and pilot commercial launches across the United States, with strategic regulatory filings underway in Europe and Asia. The company has secured 510(k) clearances for select endoscopic products in the U.S. and CE marking for certain platforms in the European Union. PAVmed collaborates with hospitals, academic medical centers, and distribution partners to support pilot programs, generate real-world evidence, and prepare for broader market access as each product advances through the approval process.
Founded in 2012, PAVmed became a publicly traded company in 2018 through a reverse merger and subsequent listing on the Nasdaq. The firm is led by Chief Executive Officer Dr. Robert L. Cohen, a physician-entrepreneur with more than two decades of experience in medical device innovation. Supporting the leadership team is a board of directors and executive officers drawn from industry, clinical research, and regulatory affairs, all united by a shared commitment to bringing next-generation therapeutic devices to market.
